Objective: Utilizing the Veterans Aging Cohort Study, the largest HIV cohort in North America, we conducted one of the few comprehensive comparisons of cancer incidence time trends in HIV-infected (HIVþ) versus uninfected persons during the antiretroviral therapy (ART) era.
Introduction
Cancer is a leading cause of death among persons living with HIV/AIDS [1] [2] [3] [4] . Before the advent of combination antiretroviral therapy (ART) in 1996, AIDSdefining cancers [ADC; Kaposi sarcoma, nonHodgkin lymphoma (NHL), and invasive cervical cancer] represented most cancer cases among HIV-infected (HIVþ) persons [5] . The introduction of ART was followed by a substantial decrease in ADC incidence rate [5] [6] [7] [8] [9] [10] [11] [12] [13] . Simultaneously, the increasing lifespan and consequent aging of the HIVþ population [14] resulted in an increased crude nonAIDS-defining cancer (NADC) incidence rate [5, 6, 8, 12, 15] and a shift in cancer burden from ADC to NADC [5] . Although the crude NADC incidence rate increased between the pre-ART and ART eras, once age and other demographic factors were taken into account, the NADC incidence rate declined [5] , remained steady [11] , or increased [12, 13] .
Cancer time trend studies restricted to the ART era have for the most part focused on a limited number of cancer types and have varied in range and recency of calendar years studied [11, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Studies of adjusted incidence rate time trends that classified NADC into broad groupings have produced inconsistent results [20, [23] [24] [25] . Evidence supports decreasing trends for lung cancer and Hodgkin lymphoma and an increasing trend for liver cancer, but results for anal cancer have been inconsistent; many nonsignificant trends for specific NADC have been observed, perhaps due to insufficient statistical power [11, [16] [17] [18] [19] [21] [22] [23] 26] . The ADC adjusted incidence rate has continued to decline during the ART era [9, 11, 17, 18, 20, 23, 24] .
Despite the continued decline of the ADC incidence rate, the relative risk (HIVþ versus uninfected) remains elevated, even in the more recent ART era [9, 11, 23] . The relative risk for NADC (grouped) [11, 12, 20, 23] and for specific NADC, including oral cavity and pharynx, anal, lung, and liver cancers and Hodgkin lymphoma, is elevated as well [27] [28] [29] . However, few studies have examined time trends in cancer relative risk during the ART era [9, 16, 18, 19, 23] . Several of these studies compared HIVþ persons with the general population using standardized incidence ratios (SIR) [18, 19] , but we are aware of only one study (from Kaiser Permanente in California during 1996-2007) that examined cancer incidence rate ratio (IRR) time trends in HIVþ versus demographically similar uninfected persons across a range of cancer groupings and specific types [23] .
Our objective was to conduct a comprehensive assessment of cancer incidence time trends during the ARTera (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) in the Veterans Aging Cohort Study (VACS), a large national HIV cohort that includes a demographically similar uninfected comparison group.
Methods
The VACS is an open cohort assembled from national Veterans Health Administration (VHA) databases (e.g., demographic, vital status, inpatient and outpatient encounters, laboratory results) with no direct researcher-patient contact [30] . VACS enrolls HIVþ veterans when they begin HIV care in the VHA and matches two uninfected veterans by age, sex, race/ ethnicity, and clinical site. Veterans Affairs Connecticut Healthcare System and Yale University Institutional Review Boards have approved this study.
We linked VACS to the Veterans Affairs Central Cancer Registry (VACCR), a national registry of cancer cases diagnosed or treated at the VHA [31] and mapped International Classification of Diseases for Oncology Third Edition [32] topography and morphology codes from VACCR records to specific cancer types, consistent with Surveillance, Epidemiology, and End Results recoding algorithms [33] . We then further classified select NADC anatomic sites (oral cavity and pharynx, anal, liver, vagina, vulva, penis) into virus-related NADC (virus-NADC; Appendix Table 1 , http://links.lww.com/ QAD/A913) and nonvirus-related NADC (nonvirus-NADC). We used the following cancer group classification: all cancer; ADC; all NADC; virus-NADC; nonvirus-NADC; nonlung, nonvirus-NADC; and poorly specified cancers (Appendix Table 1 , http:// links.lww.com/QAD/A913). For cancer group incidence rate analyses, the endpoint for a given person was the first diagnosis of a cancer type classified in the group. To calculate the proportion of cancer cases by cancer type or group, we included all incident cancer cases, not just the first diagnosis per person. For example, a person diagnosed with both prostate and colorectal cancer contributed two nonvirus-NADC cases.
For each cancer group or type and calendar period (1997-2000, 2001-2004, 2005-2008, or 2009-2012) , we used the direct method to calculate age-, sex-, and race/ethnicity-standardized incidence rates [34] stratified by HIV status; a standardized IRR (HIVþ versus uninfected); and 95% confidence intervals (95% CI). Henceforth, 'incidence rate' and 'IRR' signify standardized calculations, whereas 'crude incidence rate' signifies a nonstandardized crude incidence rate. Incidence rates provide information about HIV-status-specific absolute risk (after controlling for demographic factors), whereas IRRs provide information about risk in HIVþ relative to uninfected.
For direct standardization, we used the age (5-year groups), sex, and race/ethnicity (nonHispanic white, nonHispanic black, Hispanic, and other/unknown) person-year distribution of the entire VACS as the standard weights, with age and calendar period classified at each day of observation [35] . We calculated observation time for each person from 180 days after VACS entry date to the earliest of diagnosis date for the specific cancer group or type being analyzed, death date, loss to followup date (180 days after last VHA visit), or 30 September 2012. We excluded the first 180 days of observation time to remove prevalent cancer cases.
To calculate the incidence rate P trend across calendar periods, we used the Cochran-Armitage test of trend to calculate the one degree-of-freedom total chi-square statistic and P value [36] , taking the standardization into account. For the IRR P trend across calendar periods, we calculated the one degree-of-freedom Mantel-Haenszel chi-square statistic and P value [37, 38] .
We performed statistical analyses using SAS version 9.4 [39] . We defined statistical significance as P less than 0.05 (two sided).
Results
Between 1997 
All cancer
Although the all cancer crude incidence rate increased over the four periods in the HIVþ (P trend ¼ 0.0019, Fig. 1 ), once age-, sex-, and race/ethnicity-standardized, the incidence rate declined significantly (P trend <0.0001). In the uninfected, the increase in the crude all cancer incidence rate (P trend <0.0001) was more pronounced than in HIVþ, but there was no significant trend in the standardized incidence rate (P trend ¼ 0.074). With decreasing HIVþ incidence rates and stable uninfected incidence rates, the IRR declined (P trend <0.0001, Fig. 2 ), but remained elevated during the most recent calendar period (IRR ¼ 1.6; 95% CI: 1.5-1.7; Table 2 ).
AIDS-defining cancers
Among HIVþ, the proportion of cancer cases that were ADC decreased from 31% in 1997-2000 to 11% in 2009-2012 ( Fig. 3 ). The ADC incidence rate decreased in the HIVþ across the four periods (P trend <0.0001; Table 2 ). In the uninfected, the incidence rate increased modestly (P trend ¼ 0.014), driven by the increase in the NHL incidence rate ( Table 2 ). Resultant IRRs decreased significantly across periods (P trend <0.0001; Fig. 2 ), but remained elevated in the most recent period (IRR ¼ 5.5; 95% CI: 3.7-8.4). In the HIVþ, both the NHL and Kaposi sarcoma incidence rate declined by more than one-half between 1997-2000 and 2009-2012 (both P trends <0.0001). In the uninfected, the NHL incidence rate increased across periods (P trend ¼ 0.021), and there were no Kaposi sarcoma cases. The NHL IRR dropped from 12 (95% CI: 5.8-24) in 1997-2000 to 3.6 (95% CI: 2.3-5.5) in 2009-2012 (P trend <0.0001). Due to the small proportion of women (3%), invasive cervical cancer did not meaningfully contribute to the ADC time trends.
Virus-related nonAIDS-defining cancers
Among HIVþ, the proportion of cancer cases that were virus-NADC increased from 16% in 1997-2000 to 21% in 2009-2012 ( Fig. 3 ). In the latter period, 44% of virus-NADC were hepatocellular carcinoma (HCC) and 33% were anal squamous cell carcinoma (SCC). The virus-NADC incidence rate was stable for HIVþ (P trend ¼ 0.43, Table 2 ) but increased significantly for uninfected (P trend ¼ 0.0082), driven by an increasing HCC incidence rate trend. Consequently, the virus-NADC IRR decreased across the four periods with a borderline significant trend (P trend ¼ 0.071; Fig. 2 ), but remained elevated during the most recent period (IRR ¼ 3.5; 95% CI: 2.7-4.5; Table 2 ). The HCC incidence rate increased in HIVþ (P trend ¼ 0.043), but moreso in uninfected (P trend <0.0001), resulting in an IRR decrease from 9.8 (95% CI: 2.9-33) in 1997-2000 to 2.1 (95% CI: 1.5-2.8) in 2009-2012 (P trend ¼ 0.0002). The human papillomavirus (HPV)related oral cavity and pharynx SCC incidence rate did not change significantly for HIVþ (P trend ¼ 0.43), but decreased in the uninfected (P trend ¼ 0.023), resulting in an increasing IRR trend (P trend ¼ 0.048). We observed no trend in the anal SCC incidence rate or IRR. In HIVþ between 1997-2000 and 2001-2004, the Hodgkin lymphoma incidence rate fell from 55 to 28 cases per 100 000 person-years and then stabilized (P trend ¼ 0.047), with no IRR trend (P trend ¼ 0.79). For each mentioned virus-NADC, we found a significantly elevated IRR in the most recent calendar period.
Nonvirus-related nonAIDS-defining cancers
Among HIVþ, the proportion of cancer cases that were nonvirus-NADC increased from 51% in 1997-2000 to 68% in 2009-2012 ( Fig. 3) . Thus, the majority of incident cancer cases were nonvirus-NADC, which includes common cancer types such as colorectal, lung, and prostate. During 2009-2012, 27% of nonvirus-NADC were lung cancers and 35% were prostate cancers. We observed a decreasing trend for the HIVþ incidence rate (P trend <0.0001; Table 2 ), uninfected incidence rate (P trend ¼ 0.0011), and IRR (P ¼ 0.049; Fig. 2 ), but the IRR remained slightly elevated during the most recent period (IRR ¼ 1.2; 95% CI: 1.1-1.3). The lung cancer incidence rate decreased significantly in both HIVþ (P trend ¼ 0.0008) and uninfected (P trend ¼ 0.0017), with the IRR significantly elevated between 1.7 and 2.0 over the four periods (P trend ¼ 0.52). Lung cancer was the only nonvirus-NADC type with consistently elevated IRRs across periods. After removing lung cancer from the nonvirus-NADC group, the IRR trend was no longer significant (P trend ¼ 0.12), and the IRR moved toward the null and was only marginally or borderline significant in each calendar period.
Discussion
We utilized the largest HIV cohort in North America to conduct one of the few comprehensive assessments of cancer incidence time trends among HIVþ versus uninfected persons during the ART era. We observed a growing cancer burden among HIVþ, evidenced by an increasing crude incidence rate trend. However, after taking age, sex, and race/ethnicity into account, we observed highly significant HIVþ incidence rate declines for all cancer (25% decline between 1997-2000 and 2009-2012), ADC (55% decline), NADC (15% decline), and nonvirus-NADC (20% decline); highly significant IRR declines for all cancer (from 2.0 to 1.6) and ADC (from 19 to 5.5); and marginally or borderline significant IRR declines for NADC (from 1.6 to 1.4), virus-NADC (from 4.9 to 3.5), and nonvirus-NADC (from 1.4 to 1.2). Although these declines were encouraging, it is important to note that the all cancer incidence rate was still 60% higher in HIVþ compared with uninfected in 2009-2012, driven mainly by ADC, virus-NADC, and within the nonvirus-NADC group, lung cancer (IRR ¼ 1.8).
We found that the continuing decline in the HIVþ ADC incidence rate and the ADC IRR during the ART era that also has been observed by others [9, 11, 17, 18, 20, 23, 24] has extended through 2012 both for ADC overall and for Kaposi sarcoma and NHL, the main ADC components in our predominantly male cohort. The significant HIVþ NADC incidence rate decline that we observed during the ART era was not observed by others [11, 22] , perhaps due to shorter calendar times of observation or fewer cancer diagnoses resulting in less statistical power. However, the NADC IRR decline that we observed, which took into account the decline in the uninfected NADC incidence rate that also occurred during the observation period, was only Fig. 1 . All cancer crude and standardized incidence rates by HIV status and calendar period and P values for incidence rate period trend. HIVþ, HIV-infected; IR, incidence rate.
borderline significant, similar to the Kaiser Permanente California result [23] .
We found no evidence for a trend in the HIVþ virus-NADC incidence rate, consistent with findings from the HIV Outpatient Study [24] , but inconsistent with a study from northern Italy, which observed an increasing trend (but with no reported P trend) [20] and with the Kaiser study, which observed a significant decreasing trend [23] . However, the borderline significant decreasing trend that we observed in the virus-NADC IRR, which took into account the increasing uninfected virus-NADC incidence rate trend (driven by the increasing HCC incidence rate trend), was consistent with the significant Cancer group standardized incidence rates (per 100 000 person-years) by HIV status and calendar period, standardized incidence rate ratios with 95% confidence intervals by period, and P values for standardized incidence rate ratio period trend. ADC, AIDS-defining cancer; HIVþ, HIV-infected; IR, standardized incidence rate; IRR, standardized incidence rate ratio; NADC, nonAIDS-defining cancer; Nonvirus-NADC, nonvirus-related nonAIDS-defining cancer; Virus-NADC, virus-related nonAIDSdefining cancer. Note that Y-axis scale varies by cancer group. decreasing IRR trend observed in the Kaiser study [23] .
In the VACS cohort, HCC accounted for almost 40% of virus-NADC among HIVþ and almost 60% of virus-NADC among uninfected persons. HCC may be less common in other populations, accounting for differences in virus-NADC trends.
The significant decreasing trend we observed in the HIVþ nonvirus-NADC incidence rate was consistent with findings from the HIV Outpatient Study [24] , but inconsistent with results from northern Italy, where a borderline significant increasing trend was observed [25] and from Kaiser, where no trend was observed, either in the HIVþ incidence rate or in the IRR [23] . The decreasing nonvirus-NADC IRR trend that we observed, which took the decreasing uninfected nonvirus-NADC incidence rate trend into account, was only marginally significant. Furthermore, removal of lung cancer, the only nonvirus-NADC with an elevated IRR in each of the four periods, resulted in a nonsignificant IRR trend with marginally or borderline significant period-specific IRRs of only 1.1-1.2. This reflected the fact that most of the common epithelial cancer types, including colorectal and prostate, did not exhibit elevated incidence in HIVþ persons, consistent with the literature [27, 28] . We observed no trend in the prostate cancer incidence rate in either HIVþor uninfected persons, with the IRR consistently null across the four periods. These results suggested stable prostate specific antigen screening rates during 1996-2012, with similar screening rates in HIVþ and uninfected persons.
With respect to specific NADC types, the decreasing HIVþ incidence rate trends for lung cancer and Hodgkin For cancer group analyses, the endpoint for a given person was the first diagnosis of a cancer type classified in the group. b We used sex-specific weights to calculate penis SCC and male breast, female breast, prostate, and testicular cancer IRs. c 'z' denotes cancer types with less than 12 cases in HIVþ or uninfected over the entire study period (P trend not calculated). The following cancer types had less than 12 HIVþ cases and less than 12 uninfected cases over the entire study period and were not included in the lymphoma, and the increasing trend for HCC were consistent with previous reports [17] [18] [19] . However, we observed no trend in the lung cancer IRR, which took into account the decreasing uninfected lung cancer incidence rate trend. This result was inconsistent with studies that observed a decreasing lung cancer IRR (or SIR) trend [18, 19, 23] . Furthermore, we observed a decreasing HCC IRR trend, which was driven by the steeply increasing uninfected HCC incidence rate trend.
Other studies have observed no HCC IRR (or SIR) trend [18, 19, 23] . We observed no trend in the HIVþanal cancer incidence rate or in the IRR; trends observed in other studies have been inconsistent [16] [17] [18] [19] 22, 23, 26] .
In general, time trends in cancer incidence are determined by secular trends in the prevalence of cancer risk factors. The decreasing lung cancer and increasing HCC incidence rate trends in both HIVþand uninfected were consistent with secular trends in the US general population [40] , driven by decreasing smoking prevalence [41] and increasing duration of chronic HCV infection [42] , respectively.
Among HIVþ persons, the prevalence of traditional cancer risk factors, particularly smoking and oncogenic virus infections, is elevated [43] , although prevalence time trends have not been well characterized. Furthermore, impaired immune function and inflammation resulting from HIV infection itself are associated with appreciable cancer risk [27, 44] . The strong inverse association between CD4 þ cell count and ADC risk is well established, and evidence has accumulated in favor of a weaker, more subtle inverse association between CD4 þ cell count and risk for virus-NADC and possibly some nonvirus-NADC [27, 44] . Thus, the decreasing ADC trends were probably driven by improvements in HIV care since the introduction of ART, including higher CD4 þ cell count at diagnosis [45] , earlier postdiagnosis initiation of ART [46] , improved ART regimens [47, 48] , increased ART adherence [49] , and increased virological suppression [49, 50] . These HIV care trends likely contributed to the decreasing NADC trends as well.
We found that among HIVþ persons, the shift in cancer burden from ADC to NADC (especially nonvirus-NADC) has continued (Fig. 3) . By 2009-2012, only 11% of HIVþ cancer cases were ADC, and four of the five most commonly diagnosed cancer types (prostate, lung, HCC, NHL, and anal SCC) were NADC, although prostate cancer did not exhibit elevated incidence among HIVþ persons.
Our results have implications for cancer prevention among HIVþ persons. First, given the continued elevated ADC and NADC IRRs and the association between impaired immune function and increased ADC and, to a lesser extent, NADC risk, it is likely that even further improvements in HIV care would result in further declines in cancer incidence, especially for NHL, now the most common ADC.
Second, lung, liver, anal, and prostate cancers represent targets for prevention due to their high incidence.
Prevention research efforts in the setting of HIV infection should include smoking cessation [51, 52] ; validation and optimization of computed tomography screening for lung cancer [53, 54] , ultrasonography screening for HCC [55] , and anal dysplasia screening for anal cancer [56] ; optimization of HBV vaccination for HCC [57, 58] and HPV vaccination for HPV-related cancers [59] [60] [61] [62] [63] ; and optimization of HCV [64, 65] , HBV [57, 66] , and alcohol abuse/dependence treatment [67, 68] for HCC. Prostate specific antigen screening for prostate cancer is controversial [69] .
Our study had limitations. First, due to the paucity of women in VACS, we were unable to assess woman cancer type time trends or to generalize our results to women. Second, VACCR does not capture 10-20% of cancer cases, in part due to utilization of healthcare outside the VHA system [29, 31] , resulting in underestimation of incidence rates. However, in a validation study, we determined that IRRs are either unbiased or possibly biased downward [29] , meaning that the 'true' IRRs would be at least as high as the IRRs we observed. The elevated IRRs we observed were generally consistent with the literature [27, 28] .
Our study also had strengths. First, VACS is the largest HIV cohort in North America and one of the few to include a demographically-similar uninfected comparison group, which is superior to a general population comparison group for identifying HIV-specific effects. Second, although cancer case ascertainment was incomplete, the positive predictive value of VACCR diagnoses is high [29] . Finally, our study extended from the start of the ART era through 2012, the most extensive cancer time trends study performed to date.
In summary, after adjusting for demographic factors, we observed a generalized decline in both absolute and relative cancer incidence among HIVþ persons during the ARTera. HIVþ incidence rates declined for all cancer groups except virus-NADC, and IRRs declined for all cancer groups, although IRR trends for NADC, virus-NADC, and nonvirus-NADC were only marginally or borderline significant. In spite of these declines, the allcancer incidence rate remained 60% higher in HIVþ compared with uninfected in 2009-2012, driven mainly by elevated IRRs for ADC, virus-NADC, and lung cancer. Improved HIV care most likely contributed to the declines, and we could anticipate that further adoption of early and sustained ART combined with ongoing ART regimen enhancements will produce additional declines in cancer incidence. Research and clinical practice efforts to reduce cancer risk factor prevalence and to promote evidence-based screening could also contribute to future cancer incidence declines among HIVþ persons.
